<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: following risks could affect", fill: "#696969"},
{source: "1: following risks could affect", target: "1: operations", fill: "#696969"},
{source: "1: following risks could affect", target: "3: success depends on", fill: "#ffdead"},
{source: "3: success depends on", target: "3: Powerlink System ", fill: "#ffdead"},
{source: "3: success depends on", target: "4: demonstrated", fill: "#7b68ee"},
{source: "4: demonstrated", target: "4: investigators", fill: "#7b68ee"},
{source: "4: investigators", target: "4: acceptance", fill: "#7b68ee"},
{source: "4: acceptance", target: "4: the Powerlink System ", fill: "#7b68ee"},
{source: "4: demonstrated", target: "17: prominent devices", fill: "#7c1c05"},
{source: "17: prominent devices", target: "17: competitive challenge", fill: "#7c1c05"},
{source: "17: competitive challenge", target: "17: available both", fill: "#7c1c05"},
{source: "17: available both", target: "17: availability", fill: "#7c1c05"},
{source: "17: availability", target: "17: technologies", fill: "#7c1c05"},
{source: "17: technologies", target: "17: various phases", fill: "#7c1c05"},
{source: "17: various phases", target: "17: development", fill: "#7c1c05"},
{source: "17: development", target: "17: pharmaceutical solutions", fill: "#7c1c05"},
{source: "17: prominent devices", target: "25: Further ", fill: "#ff43a4"},
{source: "25: Further ", target: "25: international markets", fill: "#ff43a4"},
{source: "25: international markets", target: "25: government managed healthcare systems", fill: "#ff43a4"},
{source: "25: government managed healthcare systems", target: "25: control reimbursement", fill: "#ff43a4"},
{source: "25: Further ", target: "27: sufficient reimbursement", fill: "#6b8e23"},
{source: "27: sufficient reimbursement", target: "27: Powerlink System ", fill: "#6b8e23"},
{source: "27: Powerlink System ", target: "27: United States ", fill: "#6b8e23"},
{source: "27: United States ", target: "27: internationally", fill: "#6b8e23"},
{source: "27: internationally", target: "27: adversely", fill: "#6b8e23"},
{source: "27: sufficient reimbursement", target: "35: cash flow", fill: "#7f00ff"},
{source: "35: cash flow", target: "35: from operations will", fill: "#7f00ff"},
{source: "35: from operations will", target: "35: impacted by", fill: "#7f00ff"},
{source: "35: impacted by", target: "35: acceptance", fill: "#7f00ff"},
{source: "35: acceptance", target: "35: Powerlink System ", fill: "#7f00ff"},
{source: "35: Powerlink System ", target: "35: additional", fill: "#7f00ff"},
{source: "35: additional", target: "35: products competing technologies", fill: "#7f00ff"},
{source: "35: products competing technologies", target: "35: regulatory developments", fill: "#7f00ff"},
{source: "35: cash flow", target: "37: difficult", fill: "#bf94e4"},
{source: "37: difficult", target: "37: significantly from quarter", fill: "#bf94e4"},
{source: "37: significantly from quarter", target: "37: quarter which may negatively impact", fill: "#bf94e4"},
{source: "37: difficult", target: "39: operations", fill: "#03c03c"},
{source: "39: operations", target: "39: physician acceptance", fill: "#03c03c"},
{source: "39: physician acceptance", target: "39: in the Powerlink System ", fill: "#03c03c"},
{source: "39: in the Powerlink System ", target: "39: of Contents ", fill: "#03c03c"},
{source: "39: of Contents ", target: "39: future regulatory approvals", fill: "#03c03c"},
{source: "39: future regulatory approvals", target: "39: fluctuations", fill: "#03c03c"},
{source: "39: fluctuations", target: "39: expenses associated with expanding", fill: "#03c03c"},
{source: "39: expenses associated with expanding", target: "39: introduction", fill: "#03c03c"},
{source: "39: introduction", target: "39: new products by", fill: "#03c03c"},
{source: "39: new products by", target: "39: competitors", fill: "#03c03c"},
{source: "39: competitors", target: "39: pricing policies", fill: "#03c03c"},
{source: "39: pricing policies", target: "39: variations", fill: "#03c03c"},
{source: "39: variations", target: "39: foreign exchange rates", fill: "#03c03c"},
{source: "39: operations", target: "47: requirements involve", fill: "#f0ead6"},
{source: "47: requirements involve", target: "47: detailed laboratory", fill: "#f0ead6"},
{source: "47: detailed laboratory", target: "47: clinical testing procedures sampling", fill: "#f0ead6"},
{source: "47: clinical testing procedures sampling", target: "47: activities", fill: "#f0ead6"},
{source: "47: activities", target: "47: timeconsuming procedures", fill: "#f0ead6"},
{source: "47: requirements involve", target: "49: additional", fill: "#ff3800"},
{source: "49: additional", target: "49: regulatory", fill: "#ff3800"},
{source: "49: regulatory", target: "49: requirements", fill: "#ff3800"},
{source: "49: requirements", target: "49: conditions manufacturing practices", fill: "#ff3800"},
{source: "49: conditions manufacturing practices", target: "49: environmental protection fire hazard control", fill: "#ff3800"},
{source: "49: environmental protection fire hazard control", target: "49: hazardous", fill: "#ff3800"},
{source: "49: hazardous", target: "49: potentially hazardous substances", fill: "#ff3800"},
{source: "49: additional", target: "92: intellectual property", fill: "#059033"},
{source: "92: intellectual property", target: "92: negatively affected", fill: "#059033"},
{source: "92: intellectual property", target: "START_HERE", fill: "#059033"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_operations">Special operations</a></td>
      <td>Special operations (S.O.) are military activities conducted, according to NATO, by "specially designated, organized, selected, trained, and equipped forces using unconventional techniques and modes of employment". Special operations may include reconnaissance, unconventional warfare, and counter-terrorism actions, and are typically conducted by small groups of highly-trained personnel, emphasizing sufficiency, stealth, speed, and tactical coordination, commonly known as "special forces".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Powerlink_Queensland">Powerlink Queensland</a></td>
      <td>Powerlink Queensland (formally Queensland Electricity Transmission Corporation Limited) is an electricity transmission system operator owned by the Government of Queensland which operates the high-voltage electricity transmission infrastructure in Queensland.\n\n\n== History ==\nPowerlink Queensland was created in 1995  after the corporatisation and restructure of the vertically integrated Queensland power industry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sunrise_Powerlink">Sunrise Powerlink</a></td>
      <td>Sunrise Powerlink is a high-voltage power transmission line by San Diego Gas &amp; Electric (SDG&amp;E) in San Diego County, California and Imperial County, California. The project was approved by the United States Forest Service (USFS) in July 2010, the U.S. Bureau of Land Management (BLM) in January 2009 and the California Public Utilities Commission (CPUC) in December 2008.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Australia-Asia_Power_Link">Australia-Asia Power Link</a></td>
      <td>The Australia–Asia Power Link (AAPowerLink) is a proposed electricity infrastructure project that is planned to include the world's largest solar plant, the world's largest battery, and the world's longest submarine power cable. A solar farm in Northern Territory, Australia, will produce up to 20 gigawatts of electricity, most of which will be exported to Singapore, and at a later point Indonesia, by a 4,500 km (2,800 mi) 3GW HVDC transmission line.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_testing">Acceptance testing</a></td>
      <td>In engineering and its various subdisciplines, acceptance testing is a test conducted to determine if the requirements of a specification or contract are met. It may involve chemical tests, physical tests, or performance tests.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-acceptance">Self-acceptance</a></td>
      <td>Self-acceptance is acceptance of self.\n\n\n== Definition ==\nSelf-acceptance can be defined as:\n\nthe awareness of one's strengths and weaknesses,\nthe realistic (yet subjective) appraisal of one's talents, capabilities, and general worth, and,\nfeelings of satisfaction with one's self despite deficiencies and regardless of past behaviors and choices.According to Shepard, self-acceptance is an individual's satisfaction or happiness with oneself, and is thought to be necessary for good mental health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_and_commitment_therapy">Acceptance and commitment therapy</a></td>
      <td>Acceptance and commitment therapy (ACT, typically pronounced as the word "act") is a form of psychotherapy, as well as a branch of clinical behavior analysis. It is an empirically based psychological intervention that uses acceptance and mindfulness strategies along with commitment and behavior-change strategies to increase psychological flexibility.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Superintendent_of_police_(India)">Superintendent of police (India)</a></td>
      <td>Superintendent of police or SP is a senior rank in Indian Police Service or IPS. Superintendent of Police in Hindi means पुलिस अधीक्षक. They have one Star and one Ashoka emblem on their shoulders and below IPS is written.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_member_system">Additional member system</a></td>
      <td>The additional member system (AMS) is a mixed electoral system under which most representatives are elected in single-member districts (SMDs), and the other "additional members" are elected to make the seat distribution in the chamber more proportional to the way votes are cast for party lists. It is distinct from parallel voting (also known as the supplementary member system) in that the "additional member" seats are awarded to parties taking into account seats won in SMDs (referred to as compensation or "top-up"), which is not done under parallel voting (a non-compensatory method).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_director_general_of_police">Additional director general of police</a></td>
      <td>Additional Director General of Police (ADGP) is an Indian Police Service rank. Though having the maximum possible 3-star police rank just like Director General of Police,  ADGP's are considered same to DGP's.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Order_of_Australia">Order of Australia</a></td>
      <td>The Order of Australia is an honour that recognises Australian citizens and other persons for outstanding achievement and service. It was established on 14 February 1975 by Elizabeth II, Queen of Australia, on the advice of the Australian Government.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Additional_secretary_to_the_Government_of_India">Additional secretary to the Government of India</a></td>
      <td>Additional Secretary (often abbreviated as AS, GoI or Union Additional Secretary or Additional Secretary to Government of India) is a post and a rank under the Central Staffing Scheme of the Government of India. The authority for creation of this post solely rests with Cabinet of India.Additional secretary is mostly a career civil servant, generally from the Indian Administrative Service, and is a government official of high seniority.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Difficult_Couple">The Difficult Couple</a></td>
      <td>The Difficult Couple (Chinese: 难夫难妻; pinyin: Nànfū Nànqī), also translated as Die for Marriage, is a 1913 Chinese film. It is known for being the earliest Chinese feature film.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fluctuating_asymmetry">Fluctuating asymmetry</a></td>
      <td>Fluctuating asymmetry (FA), is a form of biological asymmetry, along with anti-symmetry and direction asymmetry. Fluctuating asymmetry refers to small, random deviations away from perfect bilateral symmetry.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Primordial_fluctuations">Primordial fluctuations</a></td>
      <td>Primordial fluctuations are density variations in the early universe which are considered the seeds of all structure in the universe. Currently, the most widely accepted explanation for their origin is in the context of cosmic inflation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/House_Un-American_Activities_Committee">House Un-American Activities Committee</a></td>
      <td>The House Committee on Un-American Activities (HCUA), popularly dubbed the House Un-American Activities Committee (HUAC), was an investigative committee of the United States House of Representatives, created in 1938 to investigate alleged disloyalty and subversive activities on the part of private citizens, public employees, and those organizations suspected of having either fascist or communist ties. It became a standing (permanent) committee in 1945, and from 1969 onwards it was known as the House Committee on Internal Security.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property">Intellectual property</a></td>
      <td>Intellectual property (IP) is a category of property that includes intangible creations of the human intellect. There are many types of intellectual property, and some countries recognize more than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intellectual_property_infringement">Intellectual property infringement</a></td>
      <td>An intellectual property (IP) infringement is the infringement or violation of an intellectual property right. There are several types of intellectual property rights, such as copyrights, patents, trademarks, industrial designs, and trade secrets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Indigenous_intellectual_property">Indigenous intellectual property</a></td>
      <td>Indigenous intellectual property is a term used in national and international forums to describe intellectual property that is "collectively owned" by various Indigenous peoples, and by extension, their legal rights to protect specific such property. This property includes cultural knowledge of their groups and many aspects of their cultural heritage and knowledge, including that held in oral history.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ENDOLOGIX INC /DE/      Item 1A Risk Factors             The <font color="blue">following risks <font color="blue">could affect</font></font> our business, financial results and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">risk factors should</font> be considered in <font color="blue">connection</font>     <font color="blue">with evaluating</font> the forward-looking statements contained in this Annual     Report on Form 10-K because these <font color="blue">factors could</font> cause the actual results and     <font color="blue">conditions</font> to <font color="blue">differ materially from</font> those projected in the forward-looking     statements</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success depends</font> on</font> the safety and efficacy of the <font color="blue"><font color="blue">Powerlink System</font> </font>in     <font color="blue">general use</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">demonstrated</font> the safety and efficacy of the Powerlink     System in our clinical studies with our clinical <font color="blue">investigators</font>, market     <font color="blue">acceptance</font> will <font color="blue">depend on</font> similar results with the <font color="blue"><font color="blue">Powerlink System</font> </font>in     <font color="blue">general use</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">significant</font> <font color="blue">difficult</font>ies</font> or <font color="blue">adverse events <font color="blue">encountered</font></font> in     general  use  will  impair the success of the <font color="blue"><font color="blue">Powerlink System</font> </font>and our     business</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success depends</font> on</font> the growth in the number of AAA <font color="blue">patient <font color="blue">treated with</font></font>     <font color="blue"><font color="blue">endovascular</font> devices</font></td>
    </tr>
    <tr>
      <td>Of the estimated 1dtta7 million people with AAA in the US, only about     220cmam000 are <font color="blue">diagnosed annually</font>, and of that amount only about 20cmam000 to     25cmam000  are  <font color="blue">treated with</font> an <font color="blue">endovascular</font> device</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success with</font> our     <font color="blue"><font color="blue">Powerlink System</font> </font><font color="blue">will <font color="blue">depend on</font> <font color="blue">increasing percentage</font></font> of <font color="blue">patients with</font> AAA     being <font color="blue">diagnosed at earlier stages</font> and an <font color="blue">increasing percentage</font> of those     receiving <font color="blue">endovascular</font>, as opposed to <font color="blue">open surgical procedures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Initiatives     </font>to increase screening for AAA are <font color="blue">underway but</font> are out of our control and     such general screening programs may never gain wide <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The failure     to diagnose more <font color="blue">patients with</font> AAA, at an earlier stage, will negatively     <font color="blue">impact sales</font> of the <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success depends</font> on</font> convincing a <font color="blue">concentrated customer base</font> of vascular     surgeons and a limited number of <font color="blue">interventional radiologists</font> and     <font color="blue">cardiologists</font> to use our <font color="blue">product over alternative products</font> and treatment     <font color="blue">modalities</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">physicians currently treating</font> AAA have choices in treatment     approach, one of which is <font color="blue">endovascular</font> AAA <font color="blue">stent graft placement</font></td>
    </tr>
    <tr>
      <td>There are     several competing <font color="blue">endovascular</font> stent grafts to <font color="blue">choose from</font> and that number     may increase</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font><font color="blue">revenues from sales</font> of <font color="blue">Powerlink System</font>s will     <font color="blue">depend on</font> our marketing and <font color="blue">sales team demonstrating</font> that the Powerlink     System is a superior <font color="blue">treatment alternative</font> to watchful waiting, open surgery     and  <font color="blue">competitive products</font></td>
    </tr>
    <tr>
      <td>We believe that this will require continued     <font color="blue">demonstration through clinical data</font> and personal experience of the efficacy     of the <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>While we have committed, and intend to continue to commit substantial     resources to our marketing efforts, our <font color="blue">competitors</font> have superior resources     to market and promote their <font color="blue">endovascular</font> stent graft products</td>
    </tr>
    <tr>
      <td>The most     <font color="blue">prominent devices</font> that pose a <font color="blue">competitive challenge</font> to us include:         •  Medtronic’s AneuRx, WL Gore’s Excluder, and Cook’s Zenith AAA system,     which are <font color="blue">available both</font> in the US and Europe;         •  other AAA graft Systems by Medtronic, and Johnson &amp; Johnson, which     currently have more limited <font color="blue">availability</font>; and,          •   other  <font color="blue">technologies</font> in <font color="blue">various phases</font> of <font color="blue">development</font>, including     <font color="blue">pharmaceutical solutions</font></td>
    </tr>
    <tr>
      <td>12       _________________________________________________________________    [65]Table <font color="blue">of <font color="blue">Contents       </font>    </font>   Any of these <font color="blue">treatments</font> could prove to be more <font color="blue">effective</font> or may     achieve greater market <font color="blue">acceptance</font> than the <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>Even if these     <font color="blue">treatments</font>  are  not as <font color="blue">effective</font> as the <font color="blue">Powerlink System</font>, many of the     <font color="blue">companies pursuing</font> these <font color="blue">treatments</font> and <font color="blue">technologies</font> have:         •  <font color="blue">significant</font>ly greater financial, <font color="blue">management</font> and other resources;         •  more extensive research and <font color="blue">development</font> capability;         •  <font color="blue">established market positions</font>; and,         •  <font color="blue">larger sales</font> and <font color="blue">marketing organizations</font></td>
    </tr>
    <tr>
      <td>In addition, we believe that many of the purchasers and potential     purchasers of our <font color="blue">competitors</font>’ products prefer to <font color="blue">purchase <font color="blue">medical devices</font></font>     from a <font color="blue">single source</font></td>
    </tr>
    <tr>
      <td>Accordingly, many of our <font color="blue">competitors</font> may have an     <font color="blue">advantage over us</font> because of their size and range of <font color="blue">product offerings</font></td>
    </tr>
    <tr>
      <td>Any     failure  of  our  Powerlink  System to achieve clinical and commercial     <font color="blue">acceptance</font> over our <font color="blue">competitors</font> products will harm our business</td>
    </tr>
    <tr>
      <td>If third-party payors do not <font color="blue">provide <font color="blue">reimbursement</font></font> for the use of the     <font color="blue">Powerlink System</font>, our <font color="blue">revenues may</font> be <font color="blue"><font color="blue">negatively impact</font>ed</font>             Our success in marketing the <font color="blue"><font color="blue">Powerlink System</font> </font>depends in large part on     whether  domestic  and  <font color="blue">international government health <font color="blue">administrative</font></font>     authorities, private health insurers and other <font color="blue">organizations will reimburse</font>     customers  for  the  cost  of  our  product</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>systems in     <font color="blue">international markets</font> vary <font color="blue">significant</font>ly by country and <font color="blue">by region within</font>     some  countries,  and  <font color="blue">reimbursement</font>  approvals  must be obtained on a     country-by-country  basis</td>
    </tr>
    <tr>
      <td>Further,  many  <font color="blue">international markets</font> have     <font color="blue">government managed healthcare systems</font> that control <font color="blue">reimbursement</font> for new     devices and procedures</td>
    </tr>
    <tr>
      <td>In <font color="blue">most markets there</font> are <font color="blue">private insurance systems</font>     as well as government-managed systems</td>
    </tr>
    <tr>
      <td>If sufficient <font color="blue">reimbursement</font> is not     made available for the <font color="blue">Powerlink System</font>, or any other product that we may     develop, in either the <font color="blue">United States </font>or <font color="blue">internationally</font>, the demand for our     products will be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially </font>all of our revenue is <font color="blue">generated from</font> a <font color="blue">single product</font>, the     <font color="blue">Powerlink System</font>, and any declines in the sale of this <font color="blue">product will</font>     <font color="blue">negatively impact</font> our business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">focused heavily on</font> the <font color="blue">development</font> and <font color="blue">commercial launch</font> of a     <font color="blue">single <font color="blue">technology</font></font>, the <font color="blue">Powerlink System</font>, because of limited resources</td>
    </tr>
    <tr>
      <td>If we     are unable to <font color="blue">successfully commercialize</font> the existing <font color="blue"><font color="blue">Powerlink System</font> </font>and     reach positive <font color="blue">cash flow</font> from <font color="blue">operations</font>, we will be constrained in our     ability to fund <font color="blue">development</font> and <font color="blue">commercialization</font> <font color="blue">improvements</font> and other     <font color="blue">product lines</font></td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur losses</font> for the <font color="blue">foreseeable future</font> and may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> to date have consumed a substantial amount of cash</td>
    </tr>
    <tr>
      <td>From  our  formation in 1992 to <font color="blue">December </font>31, 2005, we have incurred an     <font color="blue">accumulated deficit</font> of approximately dlra99dtta1 million, including a net loss of     dlra15dtta5 million for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We <font color="blue">only began generating</font>     <font color="blue"><font color="blue">significant</font> revenues from product sales</font> in 2005, and it is possible that we     may never achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve positive <font color="blue">cash flow</font>     from <font color="blue">operations</font> will be <font color="blue">impacted by</font> a number of factors, including market     <font color="blue">acceptance</font>  of the <font color="blue">Powerlink System</font>, our ability to develop <font color="blue">additional</font>     products, competing <font color="blue">technologies</font> and <font color="blue">regulatory</font> <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>If we are     unable to achieve <font color="blue">profitability</font>, our business will be <font color="blue"><font color="blue">negatively impact</font>ed</font></td>
    </tr>
    <tr>
      <td>Our future operating results are <font color="blue">difficult</font> to predict and may vary     <font color="blue"><font color="blue">significant</font>ly from quarter</font> to quarter, which may <font color="blue">negatively impact</font> our stock     price in the future</td>
    </tr>
    <tr>
      <td>We have <font color="blue">only commercially distributed</font> the <font color="blue"><font color="blue">Powerlink System</font> </font>in the     <font color="blue">United States </font>since late 2004 and therefore, we are unable to <font color="blue">predict future</font>     revenues  <font color="blue">derived from sales</font> of the <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>As a result, our     quarterly revenues and results of <font color="blue">operations</font> may fluctuate in the future due     to:         •  physician <font color="blue">acceptance</font> of the <font color="blue">Powerlink System</font>;         •  the conduct and results of <font color="blue">clinical trials</font>;                                         13       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>  •  the timing of, and expense in obtaining, <font color="blue">future <font color="blue">regulatory</font> approvals</font>;         •  <font color="blue">fluctuations</font> in our <font color="blue">expenses associated with expanding</font> our <font color="blue">operations</font>;         •  <font color="blue">introduction</font> of <font color="blue"><font color="blue">new products</font> by</font> our <font color="blue">competitors</font>;         •  changes in our <font color="blue">pricing policies</font> or in the <font color="blue">pricing policies</font> of our     <font color="blue">competitors</font> or suppliers;         •  <font color="blue">variations</font> in <font color="blue">foreign <font color="blue">exchange rate</font>s</font>; and,         •  changes in third-party payors’ <font color="blue">reimbursement</font> policies</td>
    </tr>
    <tr>
      <td>In addition, we believe that sales of our <font color="blue">products may</font> be lower in the     <font color="blue">fourth fiscal quarter as</font> many <font color="blue">patients choose</font> to <font color="blue">delay elective procedures</font>     during the <font color="blue">holiday season</font></td>
    </tr>
    <tr>
      <td>Therefore, we believe that period to period     <font color="blue">comparison</font>  of  our  operating results may not <font color="blue">necessarily</font> be reliable     <font color="blue">indicators</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>It is likely that in some future     period our operating results will not <font color="blue">meet investor <font color="blue">expectations</font></font> or those of     <font color="blue">public market analysts</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">unanticipated</font> change in revenues or operating results is likely to     cause  our  stock  price  to  <font color="blue">fluctuate since such</font> changes <font color="blue">reflect new</font>     information available to investors and analysts</td>
    </tr>
    <tr>
      <td>New information may cause     investors and analysts to revalue our stock, which could cause a decline in     the <font color="blue">trading price</font> of our stock</td>
    </tr>
    <tr>
      <td>Our business is subject to extensive <font color="blue">governmental regulation</font> that could make     it more expensive and time consuming for us to <font color="blue">introduce new</font> or improved     products</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">requirements</font> involve</font>     lengthy and <font color="blue">detailed laboratory</font> and clinical testing procedures, sampling     <font color="blue">activities</font>,  an  extensive  FDA  review  process, and other costly and     time-consuming procedures</td>
    </tr>
    <tr>
      <td>It often takes <font color="blue">several years</font> to satisfy these     <font color="blue">requirements</font>, depending on the <font color="blue">complexity</font> and novelty of the product</td>
    </tr>
    <tr>
      <td>We     also  are  subject  to  numerous  <font color="blue">additional</font>  licensing and <font color="blue">regulatory</font>     <font color="blue">requirements</font> relating to safe working <font color="blue">conditions</font>, <font color="blue">manufacturing</font> practices,     environmental protection, fire hazard control and disposal of <font color="blue">hazardous</font> or     potentially <font color="blue">hazardous</font> substances</td>
    </tr>
    <tr>
      <td>Some of the most important <font color="blue">requirements</font> we     face include:         •  FDA <font color="blue">approval process</font>;         •  <font color="blue">California Department of Health Services </font><font color="blue">requirements</font>;         •  ISO 9001:1994 and ENISO 13485:2003; and,         •  <font color="blue">European Union CE Mark </font><font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation may impede</font> our ability to <font color="blue">conduct continuing</font>     <font color="blue">clinical trials</font> of <font color="blue"><font color="blue">Powerlink System</font> </font><font color="blue">enhancements</font> and to <font color="blue">manufacture</font> the     <font color="blue"><font color="blue">Powerlink System</font> </font>and other <font color="blue">prospective products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation also</font>     <font color="blue">could delay</font> our marketing of <font color="blue">new products</font> for a considerable period of time     and <font color="blue">impose costly procedures on</font> our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The FDA and other <font color="blue">regulatory</font>     <font color="blue">agencies may</font> not approve any of our <font color="blue">future products on</font> a <font color="blue">timely basis</font>, if at     all</td>
    </tr>
    <tr>
      <td>Any delay in obtaining, or failure to obtain, <font color="blue">such approvals could</font>     <font color="blue">negatively impact</font> our marketing of any <font color="blue">proposed products</font> and reduce our     <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>Our  products  remain  subject to strict <font color="blue">regulatory</font> controls on     <font color="blue">manufacturing</font>, marketing and use</td>
    </tr>
    <tr>
      <td>We may be forced to modify or recall our     product after release in response to <font color="blue">regulatory</font> action or <font color="blue">unanticipated</font>     <font color="blue">difficult</font>ies  <font color="blue">encountered</font> in <font color="blue">general use</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">such action could</font> have a     material effect on the reputation of our products and on our business and     <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>Further, <font color="blue"><font color="blue">regulations</font> may</font> change, and any <font color="blue">additional</font> regulation could     limit or restrict our ability to use any of our <font color="blue">technologies</font>, which could     harm our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also</font> be subject to new federal, state or local     <font color="blue">regulations</font> that <font color="blue">could affect</font> our research and <font color="blue">development</font> programs and harm     our business in <font color="blue">unforeseen ways</font></td>
    </tr>
    <tr>
      <td>If this happens, we may have to incur     <font color="blue"><font color="blue">significant</font> costs</font> to <font color="blue">comply with such laws</font> and <font color="blue">regulations</font>, which will harm     our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not receive approval to market the <font color="blue"><font color="blue">Powerlink System</font> </font>in Japan</td>
    </tr>
    <tr>
      <td>In 2005, the <font color="blue">Japanese Ministry of Health </font>notified us that they would     not grant Shonin approval for the <font color="blue">PowerWeb System</font></td>
    </tr>
    <tr>
      <td>However, the Ministry of     Health requested that we submit the data on the FDA approved Powerlink     System and informed us that we would be able to utilize the clinical results     from our PowerWeb <font color="blue">clinical trials</font> as supplementary data</td>
    </tr>
    <tr>
      <td>We estimate that     the  <font color="blue"><font color="blue">Powerlink System</font> </font>will receive Shonin <font color="blue">approval by</font> the end of 2006</td>
    </tr>
    <tr>
      <td>However, the Ministry of Health may not grant Shonin <font color="blue">approval by</font> such time,     or at all, either of which may <font color="blue">negatively impact</font> our future results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>If we fail to increase our <font color="blue">direct <font color="blue">sales force</font></font> in a <font color="blue">timely manner</font>, our     business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We  have a limited domestic <font color="blue">direct <font color="blue">sales force</font></font> and we utilize a     <font color="blue">distribution network</font> for <font color="blue">sales outside</font> of the US As we launch <font color="blue">new products</font>     and increase our <font color="blue">marketing efforts with respect</font> to <font color="blue">existing products</font>, we     will need to <font color="blue"><font color="blue">significant</font>ly expand</font> the number of our <font color="blue">direct <font color="blue">sales personnel</font></font></td>
    </tr>
    <tr>
      <td>The <font color="blue">establishment</font> and <font color="blue">development</font> of a more extensive <font color="blue"><font color="blue">sales force</font> will</font> be     expensive and time consuming</td>
    </tr>
    <tr>
      <td>In addition, there is <font color="blue"><font color="blue">significant</font> competition</font>     for <font color="blue">sales personnel</font> experienced in <font color="blue">relevant medical</font> device sales</td>
    </tr>
    <tr>
      <td>If we are     unable to attract, motivate and retain <font color="blue">qualified <font color="blue">sales personnel</font></font> and thereby     increase our <font color="blue">sales force</font>, we may not be able to increase our revenues</td>
    </tr>
    <tr>
      <td>Our third-party <font color="blue">distributors</font> may not <font color="blue">effective</font>ly distribute our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> medical device <font color="blue">distributors</font> and <font color="blue">strategic relationships</font>     for the marketing and selling of our <font color="blue"><font color="blue">Powerlink System</font> </font><font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">depend on</font> these <font color="blue">distributors</font>’ efforts to market our product, yet we are     unable to control their <font color="blue">efforts completely</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">distributors</font> fail to     market and sell our products <font color="blue">effective</font>ly, our operating results and business     may suffer <font color="blue">substantially</font>, or we may have to make <font color="blue">significant</font> <font color="blue">additional</font>     <font color="blue">expenditures</font> or <font color="blue">concessions</font> to market our products</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">properly manage</font> our anticipated growth, our business could     suffer</td>
    </tr>
    <tr>
      <td>We may experience periods of <font color="blue">rapid growth</font> and expansion, which could     place a <font color="blue">significant</font> strain on our limited personnel and other resources</td>
    </tr>
    <tr>
      <td>In     particular, the <font color="blue">ongoing increase</font> in our <font color="blue">direct <font color="blue">sales force</font></font> will require     <font color="blue">significant</font> <font color="blue">management</font> and other <font color="blue">supporting resources</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">failure by us</font> to     manage our growth <font color="blue">effective</font>ly could have an adverse effect on our ability to     achieve our <font color="blue">development</font> and <font color="blue">commercialization</font> goals</td>
    </tr>
    <tr>
      <td>To achieve our revenue     goals,  we <font color="blue">must successfully increase production output as</font> required by     <font color="blue">customer demand</font></td>
    </tr>
    <tr>
      <td>We may in the future experience <font color="blue">difficult</font>ies in increasing     production, including <font color="blue">problems with production yields</font> and <font color="blue">quality control</font>     and assurance, component supply, and shortages of <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">problems could</font> result in delays in product <font color="blue">availability</font> and increases in     expenses</td>
    </tr>
    <tr>
      <td>Any such delay or increased expense could <font color="blue">adversely</font> affect our     ability to <font color="blue">generate revenues</font></td>
    </tr>
    <tr>
      <td>Future growth will also impose <font color="blue">significant</font>     added  <font color="blue">responsibilities on <font color="blue">management</font></font>, including the need to identify,     recruit, train and integrate <font color="blue">additional</font> employees</td>
    </tr>
    <tr>
      <td>In addition, rapid and     <font color="blue">significant</font> growth will place a strain on our <font color="blue">administrative</font> and operational     <font color="blue">infrastructure</font></td>
    </tr>
    <tr>
      <td>In order to manage our <font color="blue">operations</font> and growth we will need to     continue to improve our operational and <font color="blue"><font color="blue">management</font> controls</font>, reporting and     information <font color="blue"><font color="blue">technology</font> systems</font>, and <font color="blue">financial internal controls procedures</font></td>
    </tr>
    <tr>
      <td>If we are unable to manage our growth <font color="blue">effective</font>ly, it may be <font color="blue">difficult</font> for     us to execute our business strategy and our operating results and business     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">single vendor</font> to supply our graft material for the Powerlink     System, and any <font color="blue">disruption</font> in our supply <font color="blue">could delay</font> or <font color="blue">prevent us from</font>     producing the product for sale</td>
    </tr>
    <tr>
      <td>Currently, we rely on Bard Peripheral Vascular Systems, a subsidiary     of CR Bard, Inc, to supply us with graft material, which is a primary     component for the <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">reliance on</font> a sole source supplier     exposes our <font color="blue">operations</font> to <font color="blue">disruption</font>s in supply caused by:         •  failure of our supplier to comply with <font color="blue">regulatory</font> <font color="blue">requirements</font>;         •  any strike or work stoppage;         •  <font color="blue">disruption</font>s in shipping;         •  a <font color="blue">natural disaster</font> caused by fire, floods or <font color="blue">earthquakes</font>;         •  a <font color="blue">supply shortage</font> experienced by our sole source supplier; and,         •  the <font color="blue">fiscal health</font> and <font color="blue"><font color="blue">manufacturing</font> strength</font> of our sole source     supplier</td>
    </tr>
    <tr>
      <td>Although we retain a <font color="blue">significant</font> stock of the graft material, the     occurrence of any of the above <font color="blue">disruption</font>s in supply or other unforeseen     events that could cause a <font color="blue">disruption</font> in <font color="blue">supply from</font> our <font color="blue">sole source graft</font>     supplier                                         15       _________________________________________________________________    [68]Table of <font color="blue">Contents       </font>may  cause  us to halt or experience a <font color="blue">disruption</font> in <font color="blue">manufacturing</font> the     <font color="blue">Powerlink System</font></td>
    </tr>
    <tr>
      <td>Because we do not have <font color="blue">alternative suppliers</font>, our sales     and <font color="blue">profitability</font> would be harmed in the event of a <font color="blue">disruption</font></td>
    </tr>
    <tr>
      <td>If we are unable to protect our <font color="blue">intellectual property</font>, our business may be     <font color="blue">negatively affected</font></td>
    </tr>
    <tr>
      <td>The market for <font color="blue">medical devices</font> is subject to <font color="blue">frequent <font color="blue">litigation</font></font>     regarding patent and other <font color="blue">intellectual property</font> rights</td>
    </tr>
    <tr>
      <td>It is possible that     our patents or <font color="blue">licenses may</font> not <font color="blue">withstand challenges</font> made by others or     protect our <font color="blue">rights adequately</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in large part on our ability to secure <font color="blue">effective</font>     <font color="blue">patent protection</font> for our products and processes in the <font color="blue">United States </font>and     <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>We  have filed and intend to continue to <font color="blue">file patent</font>     <font color="blue">applications</font> for <font color="blue">various aspects</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, we face the     risks that:         •  we may fail to <font color="blue">secure necessary patents prior</font> to or after obtaining     <font color="blue">regulatory</font> clearances, thereby permitting <font color="blue">competitors</font> to <font color="blue">market competing</font>     products; and,          •   our  already-granted  patents  may be re-examined, re-issued or     invalidated</td>
    </tr>
    <tr>
      <td>We also own <font color="blue">trade secrets</font> and <font color="blue">confidential</font> information that we try to     protect by entering into <font color="blue">confidential</font>ity <font color="blue">agreements</font> with other parties</td>
    </tr>
    <tr>
      <td>However, the <font color="blue">confidential</font>ity <font color="blue">agreements</font> may not be honored or, if breached,     we may not have sufficient remedies to protect our <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>Further,  our <font color="blue">competitors</font> may <font color="blue">independently</font> learn our <font color="blue">trade secrets</font> or     develop  similar  or  superior  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>To  the extent that our     <font color="blue">consultants</font>, key employees or others apply <font color="blue">technological</font> information to our     projects that they develop <font color="blue">independently</font> or others develop, disputes may     arise regarding the ownership of <font color="blue">proprietary</font> rights to such information, and     such disputes may not be resolved in our favor</td>
    </tr>
    <tr>
      <td>If we are unable to protect     our <font color="blue">intellectual property</font> adequately, our business and <font color="blue">commercial prospects</font>     <font color="blue">likely will suffer</font></td>
    </tr>
    <tr>
      <td>If our products or <font color="blue">processes infringe upon</font> the <font color="blue">intellectual property</font> of our     <font color="blue">competitors</font>, the sale of these <font color="blue">products may</font> be challenged and we may have to     <font color="blue">defend costly</font> and time-consuming infringement claims</td>
    </tr>
    <tr>
      <td>We may need to engage in expensive and <font color="blue">prolonged <font color="blue">litigation</font></font> to assert     any of our rights or to determine the scope and validity of rights claimed     by other parties</td>
    </tr>
    <tr>
      <td>With <font color="blue">no certainty</font> as to the outcome, <font color="blue">litigation</font> could be     <font color="blue">too expensive</font> for us to pursue</td>
    </tr>
    <tr>
      <td>Our failure to prevail in <font color="blue">such <font color="blue">litigation</font></font> or     our failure to <font color="blue">pursue <font color="blue">litigation</font> could</font> result in the loss of our rights that     <font color="blue">could hurt</font> our business <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>In addition, the laws of some foreign     countries do not protect our <font color="blue">intellectual property</font> rights to the <font color="blue">same extent</font>     as the laws of the United States, if at all</td>
    </tr>
    <tr>
      <td>Our failure to obtain rights to <font color="blue">intellectual property</font> of <font color="blue">third parties</font>     or the potential for <font color="blue">intellectual property</font> <font color="blue">litigation</font> could force us to do     one or more of the following:         •  stop selling, making or using our products that use the disputed     <font color="blue">intellectual property</font>;         •  obtain a <font color="blue">license from</font> the <font color="blue">intellectual property</font> owner to continue     selling, making, licensing or using our products, which license may not be     <font color="blue">available on reasonable terms</font>, or at all;         •  redesign our products, processes or services; and,         •  subject us to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>If any of the foregoing occurs, we may be unable to <font color="blue">manufacture</font> and     sell our products or license our <font color="blue">technology</font> and <font color="blue">may suffer severe financial</font>     harm</td>
    </tr>
    <tr>
      <td>Whether or not an <font color="blue">intellectual property</font> claim is valid, the cost of     responding to it, in terms of legal fees and expenses and the diversion of     <font color="blue">management</font> resources, could harm our business</td>
    </tr>
    <tr>
      <td>Our sales in <font color="blue">international markets</font> subject us to <font color="blue">foreign currency exchange</font>     and <font color="blue">costs which could harm</font> our business</td>
    </tr>
    <tr>
      <td>A portion of our revenues are <font color="blue">derived from sales</font> outside the United     States</td>
    </tr>
    <tr>
      <td>For the fiscal years ended <font color="blue">December </font>31, 2005, 2004, and 2003,     <font color="blue">International </font>sales were 30prca, 86prca, and 86prca of <font color="blue">total product revenue</font>,                                         16       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font><font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Foreign <font color="blue">exchange gains</font> or losses as a result of <font color="blue">exchange rate</font>     <font color="blue">fluctuations</font>  in any <font color="blue">given period could harm</font> our operating results and     <font color="blue">negatively impact</font> our revenues</td>
    </tr>
    <tr>
      <td>Additionally, if the <font color="blue">effective</font> price of our     products were to increase as a result of <font color="blue">fluctuations</font> in foreign currency     <font color="blue">exchange rate</font>s, demand for our <font color="blue">products could decline</font> and <font color="blue">adversely</font> affect     our results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">effective</font>ly manage our inventory held <font color="blue">on <font color="blue">consignment</font> by</font>     our <font color="blue">intended customers</font>, we will not achieve our expected results</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">Powerlink System</font> </font>is <font color="blue">sold primarily on</font> a <font color="blue"><font color="blue">consignment</font> basis</font> to     <font color="blue">hospitals which purchase</font> our <font color="blue">product as</font> they use it</td>
    </tr>
    <tr>
      <td>In these <font color="blue">consignment</font>     locations, we do not have <font color="blue">physical possession</font> of our products</td>
    </tr>
    <tr>
      <td>We therefore     <font color="blue">must rely on</font> information from our <font color="blue">customers as well as periodic inspections</font>     by our <font color="blue">sales personnel</font> and <font color="blue"><font color="blue">third party</font> inventory auditors</font> to determine when     our products have been used</td>
    </tr>
    <tr>
      <td>Our efforts to strengthen our monitoring and     <font color="blue">management</font> of <font color="blue">consigned inventory may</font> not be adequate to <font color="blue">meaningfully reduce</font>     the  risk  of <font color="blue">inventory loss</font></td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">effective</font>ly manage     <font color="blue">appropriate consigned inventory levels</font>, we may suffer <font color="blue">inventory loss</font>es which     will reduce our operating results</td>
    </tr>
    <tr>
      <td>We <font color="blue">may face product <font color="blue">liability</font></font> claims that could result in <font color="blue">costly <font color="blue">litigation</font></font>     and <font color="blue">significant</font> liabilities</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>and marketing of our commercial products, and clinical     testing  of  our  products under <font color="blue">development</font>, may expose us to product     <font color="blue">liability</font>  claims</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we have, and intend to maintain, product     <font color="blue">liability</font> insurance, the <font color="blue">coverage limits</font> of our <font color="blue">insurance policies may</font> not     be adequate and one or more successful claims <font color="blue">brought against us may</font> have a     material  adverse  effect  on  our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Additionally, adverse product <font color="blue">liability</font> actions could negatively affect the     reputation and sales of our products, our ability to obtain and maintain     <font color="blue">regulatory</font> approval for our products and may divert <font color="blue">management</font>’s attention     from other matters</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> are <font color="blue">capital intensive</font>, and we may need to raise <font color="blue">additional</font>     funds in the future to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font> are <font color="blue">capital intensive</font></td>
    </tr>
    <tr>
      <td>Although we believe that our     <font color="blue">existing cash resources will</font> be sufficient to meet our anticipated cash     needs for <font color="blue">operations</font> and planned capital <font color="blue">requirements</font> through at least     <font color="blue">December </font>31,  2006, we may require <font color="blue">additional</font> capital to fund on-going     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our  cash <font color="blue">requirements</font> in the <font color="blue">future may</font> be <font color="blue">significant</font>ly     <font color="blue">different from</font> our current estimates and <font color="blue">depend on</font> many factors, including:         •  the results of our <font color="blue">commercialization</font> efforts for the <font color="blue">Powerlink System</font>;         •  the time and costs involved in obtaining <font color="blue">additional</font> <font color="blue">regulatory</font>     approvals;         •  the costs involved in obtaining and enforcing patents or any <font color="blue">litigation</font>     by <font color="blue">third parties</font> regarding <font color="blue">intellectual property</font>;         •  the <font color="blue">establishment</font> of high volume <font color="blue">manufacturing</font> and <font color="blue">increased sales</font> and     <font color="blue">marketing capabilities</font>; and,         •  our success in <font color="blue">entering into collaborative relationships with</font> other     parties</td>
    </tr>
    <tr>
      <td>To finance these <font color="blue">activities</font>, we <font color="blue">may seek funds through borrowings</font> or     through <font color="blue">additional</font> rounds of financing, including private or <font color="blue">public equity</font>     or <font color="blue">debt offerings</font> and <font color="blue">collaborative arrangements with corporate partners</font></td>
    </tr>
    <tr>
      <td>We     may be unable to <font color="blue">raise funds on</font> favorable terms, or at all</td>
    </tr>
    <tr>
      <td>In addition, the     sale of <font color="blue">additional</font> equity or <font color="blue">convertible <font color="blue">debt securities</font> could</font> result in     <font color="blue">additional</font> dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we borrow <font color="blue">additional</font> funds or     issue  <font color="blue">debt securities</font>, these <font color="blue">securities could</font> have rights superior to     holders of our <font color="blue">common stock</font>, and <font color="blue">could contain covenants</font> that <font color="blue">will restrict</font>     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We might have to obtain <font color="blue">funds through arrangements with</font>     <font color="blue">collaborative partners</font> or others that may require us to <font color="blue">relinquish</font> rights to     our <font color="blue">technologies</font>, product candidates or products that we <font color="blue">otherwise would</font> not     <font color="blue">relinquish</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we might have to delay,     scale back or <font color="blue">eliminate one</font> or more of our <font color="blue">development</font> programs, which could     <font color="blue">significant</font>ly impair our ability to operate our business</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>Our <font color="blue">operations</font> are <font color="blue"><font color="blue">currently conduct</font>ed at</font> a <font color="blue">single location</font> that may be at     risk from <font color="blue">earthquakes</font> or other <font color="blue">natural disaster</font>s</td>
    </tr>
    <tr>
      <td>We  <font color="blue">currently conduct</font> all of our <font color="blue">manufacturing</font>, <font color="blue">development</font> and     <font color="blue">management</font> <font color="blue">activities</font> at a <font color="blue">single location</font> in Irvine, California, near known     earthquake  fault  zones</td>
    </tr>
    <tr>
      <td>We  have <font color="blue">taken precautions</font> to safeguard our     <font color="blue">facilities</font>, including insurance, health and <font color="blue">safety protocols</font>, and off-site     storage of <font color="blue">computer data</font></td>
    </tr>
    <tr>
      <td>However, any future <font color="blue">natural disaster</font>, such as an     earthquake, could cause substantial delays in our <font color="blue">operations</font>, damage or     destroy  our  equipment or inventory, and cause us to incur <font color="blue">additional</font>     expenses</td>
    </tr>
    <tr>
      <td>A <font color="blue">disaster could seriously harm</font> our business and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The insurance coverage we maintain against <font color="blue">earthquakes</font> and other     <font color="blue">natural disaster</font>s may not be adequate to cover our losses in any particular     case</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">stock may fluctuate unpredictably</font> in response to factors     unrelated to our operating performance</td>
    </tr>
    <tr>
      <td>The <font color="blue">stock market periodically</font> experiences <font color="blue">significant</font> price and volume     <font color="blue">fluctuations</font> that are unrelated to the operating performance of particular     companies</td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may cause the <font color="blue">market price</font> of our     <font color="blue">common stock</font> to drop</td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">market price</font> of securities of small     medical device companies, like ours, has been very unpredictable and may     vary in response to:         •  <font color="blue">announcements by us</font> or our <font color="blue">competitors</font> concerning <font color="blue">technological</font>     <font color="blue">innovations</font>;         •  <font color="blue">introduction</font>s of <font color="blue">new products</font>;         •  FDA and foreign <font color="blue">regulatory</font> actions;         •  <font color="blue">development</font>s or disputes relating to patents or <font color="blue">proprietary</font> rights;         •  failure of our results of <font color="blue">operations</font> to meet the <font color="blue">expectations</font> of stock     market analysts and investors;         •  changes in stock market analyst <font color="blue">recommendations</font> regarding our common     stock;         •  changes in healthcare policy in the <font color="blue">United States </font>or other countries;     and,         •  general stock market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Some provisions of our <font color="blue">charter documents may</font> make <font color="blue">takeover attempts</font>     <font color="blue">difficult</font>, which could depress the price of our stock and inhibit your     ability to receive a <font color="blue">premium price</font> for your shares</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our amended and restated <font color="blue">certificate</font> of incorporation     could make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire control of our     business,  even  if  such change in <font color="blue">control would</font> be <font color="blue">beneficial</font> to our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our amended and restated <font color="blue">certificate</font> of <font color="blue">incorporation allows</font>     our board of <font color="blue">directors</font> to issue up to <font color="blue">five million shares</font> of <font color="blue">preferred stock</font>     and to fix the rights and <font color="blue">preferences</font> of <font color="blue">such shares without stockholder</font>     approval</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such issuance could</font> make it more <font color="blue">difficult</font> for a <font color="blue">third party</font>     to  acquire  our  business  and may <font color="blue">adversely</font> affect the rights of our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> is <font color="blue">divided into three</font>     classes for <font color="blue">staggered terms</font> of <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may delay</font>,     deter or prevent a change in control of us, <font color="blue">adversely</font> affecting the market     price of our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>